IMS Health Inc. / Novartis / Immunovaccine Inc. / ImmunoVaccine Technologies Inc. / Defence Research / Dendreon / GlaxoSmithKline / Merck / SectorSpeak Inc. / Development Canada / Wyeth / DEVELOPMENT AND STRATEGY Development The Company / A. COMPANY OVERVIEW Immunovaccine / U.S. Partners / Dana / Pfizer / Fiscal 2010 / Rhino Resources Inc. / Schering-Plough / Sanofi Pasteur / formulating Dana-Farber’s HIV protein antigens / /
Country
Canada / United States / /
Currency
USD / /
Event
Accounting Change / Business Partnership / FDA Phase / Employment Change / M&A / Reorganization / Name Change / /
Facility
Dana-Farber Cancer Institute / Dalhousie University / Mr. Hall / Company’s pipeline / National Cancer Institute / /
IndustryTerm
stage biotechnology / lab chemicals / research services / pharmaceutical industry / human health applications / manufacturing method development / vaccine products / food animals / human pharmaceutical market / potential applications / treatment of cancer / public relations firms / external auditors / enhancement technologies / manufacturing / sector spanning veterinary pharmaceuticals / clinical site / clinical research site / animal healthcare activities / chemicals / animal healthcare / delivery technology / contract manufacturing facilities / purchased dedicated equipment / manufacturing methods / cancer treatment / oil / communications expenses / potent delivery technology / animal health care applications / therapeutic cancer vaccine / enhancement technology / human and animal vaccine products / infectious disease products / /
MarketIndex
TSX / /
MedicalCondition
aeruginosa Pseudomonas / HIV / H5N1 pandemic influenza / prostate cancers / therapeutic cancer / Hepatitis B / Pseudomonal infections / Pseudomonal bacteremia / injury / septic shock / hepatitis / prostate cancer / tumor / hospital-acquired infection / cancer / tumors / malaria / Pseudomonas infections / ovarian and prostate cancer / AIDS / infection / anthrax / infectious disease / successful therapeutic cancer / breast and prostate cancer / Pseudomonal endocarditis / Pseudomonas / DF / early-stage infectious disease / preclinical therapeutic cancer / comparable alum-adjuvanted anthrax / cystic fibrosis / comprehensive cancer / brain abscess / congestive heart failure / breast cancers / burn / single-dose infectious disease / smaller tumors / chronic obstructive pulmonary disease / residual cancer / seasonal and pandemic influenza / prophylactic Pseudomonas / critical tumor / pandemic influenza / infectious diseases / next five years cancer / Acellular pertussis / Cough / /
MedicalTreatment
vaccination / surgery / radiation treatments / chemotherapy / /
Organization
Harvard Cancer Center / Institutional Review Board / Department of Fisheries and Oceans / Company’s Audit Committee / Dalhousie University / Harvard Medical School / National Cancer Institute / Department of Fisheries / Dana-Farber Cancer Institute / Centers for Disease Control and Prevention / Scientific Advisory Board / U.S Food and Drug Administration / Atlantic Canada Opportunities Agency / Center for AIDS Research / /
Management’s Report on Financial Position and Operating Results For the three month period ended March 31, 2010 MANAGEMENT DISCUSSION AND ANALYSIS (“MD&A”) The following analysis provides a review of the unaudited